Glycogen synthase kinase-3 beta inhibitors as novel cancer treatments and modulators of antitumor immune responses

As a kinase at the crossroads of numerous metabolic and cell growth signaling pathways, glycogen synthase kinase-3 beta (GSK-3β) is a highly desirable therapeutic target in cancer. Despite its involvement in pathways associated with the pathogenesis of several malignancies, no selective GSK-3β inhib...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Cancer Biol Ther
Autors principals: Sahin, Ilyas, Eturi, Aditya, De Souza, Andre, Pamarthy, Sahithi, Tavora, Fabio, Giles, Francis J., Carneiro, Benedito A.
Format: Artigo
Idioma:Inglês
Publicat: Taylor & Francis 2019
Matèries:
Review
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC6606036/
https://ncbi.nlm.nih.gov/pubmed/30975030
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1080/15384047.2019.1595283
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars